Ribavirin can be reduced from 800mg to 400mg in hepatitis C patients with genotype 3

Source: Inpharma, Volume 1, Number 1647, 2008-07-19 , pp. 9-9(1)

Keywords: Hepatitis-C, treatment; Peginterferon-alfa-2a, therapeutic use; Pharmacogenetics; Ribavirin, therapeutic use

Document Type: Research article

Links for this article

http://www.ingentaconnect.com/adis/inp/2008/00000001/00001647/art00031
http://openurl.ingenta.com/content?genre=article&issn=1173-8324&volume=1&issue=1647&spage=9&epage=9